Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis

Abstract

Achieving high PrEP coverage by offering CAB-LA can impact the HIV epidemic substantially if rolled out without delays. These PrEP expansions may be efficient in settings with high HIV incidence (like Atlanta) but not in settings with low HIV incidence (like Montreal and the Netherlands).